Abiopharma

🔍 Aljomaih Automotive Co. (Executive)

Company: Xos, Inc. (XOS)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Sold 237,925 shares of Convertible Note at $71.451 per share (Derivative)
  Date: 2026-05-08 | Code: J | Expires: 2028-02-11 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2, F5, F3, F4, F6
• Acquired 1,416,666 shares of Convertible Note at $12.0 per share (Derivative)
  Date: 2026-05-08 | Code: J | Expires: 2028-02-11 | equity_swap_involved: 0 | shares_owned_after: 1,416,666.00 | transaction_form_type: 4 | Footnotes: F1, F2, F5, F3, F4, F6
• Sold 125,000 shares of Convertible Note at $12.0 per share (Derivative)
  Date: 2026-05-11 | Code: J | Expires: 2028-02-11 | equity_swap_involved: 0 | shares_owned_after: 1,291,666.00 | transaction_form_type: 4 | Footnotes: F7, F8, F9, F3, F8, F10

Footnotes:

• F1: Prior to the Third Amendment and Restatement, principal amounts of the Convertible Note were convertible at the holder's election into shares of Common Stock of the issuer at a conversion price of $71.451 per share. Following the Third Amendment and Restatement, principal amounts of the Convertible Note are convertible at the holder's election into shares of Common Stock of the issuer at a conversion price of $12.00 per share. Accrued interest on the Convertible Note is payable by the Issuer in shares of common stock ("Interest Shares") at a conversion price equal to a market-based price (the "10-day VWAP," as defined in the Convertible Note) measured on the date of payment.
• F2: On May 8, 2026, the Reporting Person and the Issuer amended and restated the terms of the Convertible Promissory Note originally issued August 11, 2022, primarily to reduce the conversion price from $71.451 per share to $12.00 per share (the "Third Amendment and Restatement").
• F3: The principal amount plus any accrued and unpaid interest was convertible at the holder's election after November 9, 2022. However, under certain circumstances, the number of Interest Shares could be limited, in which case interest amounts payable in excess of such limit shall instead be payable within five business days of the earlier of (x) August 11, 2026 and (y) the date the Company receives stockholder approval to issue more than the limit in respect of conversion of the Convertible Note, as amended.
• F4: As a result of the Third Amendment and Restatement, the conversion price of the Convertible Note was reduced from $71.451 per share to $12.00 per share, which resulted in the number of shares of Common Stock issuable upon conversion of principal increasing from 237,925 to 1,416,666.
• F5: This was an amendment affecting the conversion price of the principal amount and the number of shares issuable upon such conversion, not a purchase or sale.
• F6: The $17,000,000 principal amount of Convertible Notes outstanding at the time of the Third Amendment and Restatement was convertible into 1,416,666 shares of Common Stock at $12.00 per share. Column 9 does not include any interest accrued on the Convertible Note since August 11, 2025 (at a rate of 10% per annum), which may be converted into Interest Shares at the 10-day VWAP on the date of payment, subject to certain restrictions.
• F7: On May 11, 2026, the issuer made a scheduled repayment of $1.5 million principal amount of the Convertible Note.
• F8: The $1.5 million principal amount repaid was convertible into an aggregate of 125,000 shares of common stock, par value $0.0001 per share, of the issuer.
• F9: $1.5 million principal amount of the Convertible Note was repaid and extinguished for face value.
• F10: The $15,500,000 principal amount of Convertible Notes outstanding immediately following the transaction was convertible into 1,291,666 shares of Common Stock at $12.00 per share. Column 9 does not include any interest accrued on the Convertible Note since August 11, 2025 (at a rate of 10% per annum), which may be converted into Interest Shares at the 10-day VWAP on the date of payment, subject to certain restrictions (see Footnote 3).